Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Revolution Medicines (RVMD) Shares Outstanding (Weighted Average): 2019-2025

Historic Shares Outstanding (Weighted Average) for Revolution Medicines (RVMD) over the last 7 years, with Sep 2025 value amounting to $186.9 million.

  • Revolution Medicines' Shares Outstanding (Weighted Average) rose 11.91% to $186.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $186.9 million, marking a year-over-year increase of 11.91%. This contributed to the annual value of $168.2 million for FY2024, which is 53.53% up from last year.
  • As of Q3 2025, Revolution Medicines' Shares Outstanding (Weighted Average) stood at $186.9 million, which was up 0.36% from $186.3 million recorded in Q2 2025.
  • Over the past 5 years, Revolution Medicines' Shares Outstanding (Weighted Average) peaked at $186.9 million during Q3 2025, and registered a low of $73.4 million during Q1 2021.
  • For the 3-year period, Revolution Medicines' Shares Outstanding (Weighted Average) averaged around $149.1 million, with its median value being $165.0 million (2024).
  • Data for Revolution Medicines' Shares Outstanding (Weighted Average) shows a peak YoY skyrocketed of 82.00% (in 2024) over the last 5 years.
  • Over the past 5 years, Revolution Medicines' Shares Outstanding (Weighted Average) (Quarterly) stood at $73.7 million in 2021, then grew by 20.50% to $88.8 million in 2022, then climbed by 23.40% to $109.6 million in 2023, then skyrocketed by 53.53% to $168.2 million in 2024, then climbed by 11.91% to $186.9 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $186.9 million for Q3 2025, versus $186.3 million for Q2 2025 and $185.9 million for Q1 2025.